You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClobetasol propionate
Accession NumberDB01013  (APRD00876)
TypeSmall Molecule
GroupsApproved
DescriptionA derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than fluocinonide, it is used topically in treatment of psoriasis but may cause marked adrenocortical suppression. [PubChem]
Structure
Thumb
Synonyms
21-chloro-9-fluoro-11β,17-dihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-propionate
clobetasol 17-propanoate
clobetasol 17-propionate
Clobetasol propionate E
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-clobetasol Propionate Cream 0.05%Cream.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Alti-clobetasol Propionate Ont 0.05%Ointment.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Alti-clobetasol Propionate Scalp Application 0.05%Liquid.05 %TopicalAltimed Pharma Inc.1993-12-312001-09-05Canada
Clobetasol Cream 0.05%Cream0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
Clobetasol Ointment 0.05%Ointment0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
Clobetasol PropionateAerosol, foam.5 mg/gTopicalRenaissance Pharma, Inc.2014-02-06Not applicableUs
Clobetasol PropionateAerosol, foam.5 mg/gTopicalPrasco, Laboratories2010-01-152016-03-04Us
Clobetasol PropionateLotion.5 mg/mLTopicalPaddock Laboratories, Inc.2012-01-03Not applicableUs
Clobetasol PropionateSpray.05 g/mLTopicalActavis Pharma Company2015-08-28Not applicableUs
Clobetasol PropionateShampoo.05 g/100mLTopicalSandoz2011-12-22Not applicableUs
Clobetasol PropionateAerosol, foam.5 mg/gTopicalPhysicians Total Care, Inc.2011-08-16Not applicableUs
Clobetasol Propionate EmulsionAerosol, foam.5 mg/gTopicalRenaissance Pharma, Inc.2014-02-06Not applicableUs
Clobetasol Propionate EmulsionAerosol, foam.5 mg/gTopicalPrasco, Laboratories2013-02-012015-11-30Us
Clobetasol Scalp Application 0.05%Ointment0.05 %TopicalPrempharm Inc1996-12-232005-08-05Canada
ClobexShampoo.05 g/100mLTopicalGalderma2004-03-01Not applicableUs
ClobexLotion.05 g/100mLTopicalGalderma2003-08-01Not applicableUs
ClobexSpray.05 g/mLTopicalGalderma2005-10-27Not applicableUs
ClobexSpray.5 mg/mLTopicalPhysicians Total Care, Inc.2006-01-23Not applicableUs
ClobexLotion.05 mL/100mLTopicalPhysicians Total Care, Inc.2006-08-16Not applicableUs
Clobex LotionLotion0.05 %TopicalGalderma2005-12-092016-08-04Canada
Clobex ShampooShampoo0.05 %TopicalGalderma2004-12-15Not applicableCanada
Clobex SpraySolution0.05 %TopicalGalderma2007-12-19Not applicableCanada
Dermovate CreamCream0.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-09-07Not applicableCanada
Dermovate Crm 0.05%Cream.05 %TopicalGlaxo Canada Inc1976-12-312000-08-02Canada
Dermovate OintmentOintment.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-12-20Not applicableCanada
Dermovate Ont 0.05%Ointment.05 %TopicalGlaxo Canada Inc1976-12-312000-08-02Canada
Dermovate Scalp ApplicationSolution.05 %TopicalTaropharma, A Division Of Taro Pharmaceuticals Inc.2001-06-25Not applicableCanada
Dermovate Scalp Application .05%Liquid.05 %TopicalGlaxo Canada Inc1980-12-312001-08-01Canada
Mylan-clobetasol CreamCream0.05 %TopicalMylan Pharmaceuticals1993-12-31Not applicableCanada
Mylan-clobetasol OintmentOintment0.05 %TopicalMylan Pharmaceuticals1993-12-31Not applicableCanada
Mylan-clobetasol Scalp ApplicationLotion0.05 %TopicalMylan Pharmaceuticals1996-09-10Not applicableCanada
Novo-clobetasol Crm 0.05%Cream.05 %TopicalNovopharm Limited1996-12-31Not applicableCanada
Novo-clobetasol Ointment - 0.05%Ointment.05 %TopicalNovopharm Limited1996-12-31Not applicableCanada
OluxAerosol, foam.5 mg/gTopicalPrestium Pharma, Inc.2014-02-07Not applicableUs
OluxAerosol, foam.5 mg/gTopicalPhysicians Total Care, Inc.2005-09-15Not applicableUs
Olux-EAerosol, foam0.05 %TopicalGlaxosmithkline Inc2013-02-04Not applicableCanada
Olux-EAerosol, foam.5 mg/gTopicalPrestium Pharma, Inc.2007-02-12Not applicableUs
Penta-clobetasol CreamCream.05 %TopicalPentapharm Ltd.Not applicableNot applicableCanada
PMS-clobetasolCream0.05 %TopicalPharmascience Inc2011-09-09Not applicableCanada
PMS-clobetasolOintment0.05 %TopicalPharmascience Inc2011-02-21Not applicableCanada
PMS-clobetasol CreamCream0.05 %TopicalPharmascience Inc1998-03-06Not applicableCanada
PMS-clobetasol OintmentOintment0.05 %TopicalPharmascience Inc1998-03-06Not applicableCanada
PMS-clobetasol Scalp ApplicationLiquid0.05 %TopicalPharmascience Inc1998-06-18Not applicableCanada
Ratio-clobetasolCream0.05 %TopicalTeva1992-12-31Not applicableCanada
Ratio-clobetasolLotion0.05 %TopicalTeva1992-12-31Not applicableCanada
Ratio-clobetasolOintment0.05 %TopicalTeva1992-12-31Not applicableCanada
Taro-clobetasol Cream USP, 0.05%Cream0.05 %TopicalTaro Pharmaceuticals, Inc.2002-04-22Not applicableCanada
Taro-clobetasol Ointment USP, 0.05%Ointment0.05 %TopicalTaro Pharmaceuticals, Inc.2002-04-22Not applicableCanada
Taro-clobetasol Topical Solution USP, 0.05%Solution0.05 %TopicalTaro Pharmaceuticals, Inc.2002-04-22Not applicableCanada
TemovateGel.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1994-04-29Not applicableUs
TemovateCream.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1994-06-172017-03-01Us
TemovateOintment.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1985-12-272016-10-13Us
TemovateCream.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1985-12-272016-10-13Us
Temovate Scalp ApplicationSolution.5 mg/mLTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1990-02-22Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clobetasol PropionateGel.5 mg/gTopicalTeligent Pharma, Inc.2017-03-06Not applicableUs
Clobetasol PropionateLotion.05 g/100mLTopicalActavis Mid Atlantic LLC,2012-01-03Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalA S Medication Solutions1996-07-08Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalRebel Distributors2010-06-07Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalA S Medication Solutions2010-06-07Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalPreferreed Pharmaceuticals Inc.2012-04-23Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalPhysicians Total Care, Inc.1997-05-02Not applicableUs
Clobetasol PropionateGel.05 mg/gTopicalDirectrx2015-01-01Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1996-02-23Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1999-02-08Not applicableUs
Clobetasol PropionateSpray.5 mg/mLTopicalPaddock Laboratories, Inc.2015-01-02Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalPreferreed Pharmaceuticals Inc.2014-03-05Not applicableUs
Clobetasol PropionateShampoo.05 g/100mLTopicalPerrigo New York Inc.2012-08-10Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalRebel Distributors2010-06-07Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalA S Medication Solutions1996-07-08Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateLotion.05 mg/100mLTopicalTeligent Pharma, Inc.2016-11-29Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalPhysicians Total Care, Inc.2005-03-02Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalPreferreed Pharmaceuticals Inc.2013-04-19Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1996-09-30Not applicableUs
Clobetasol PropionateAerosol, foam.5 mg/gTopicalPerrigo New York Inc.2008-03-20Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalPreferreed Pharmaceuticals Inc.2012-01-30Not applicableUs
Clobetasol PropionateLotion.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.2012-07-02Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalA S Medication Solutions1996-07-12Not applicableUs
Clobetasol PropionateGel.5 mg/gTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalA S Medication Solutions2014-02-03Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalTaro Pharmaceuticals U.S.A., Inc.1998-11-16Not applicableUs
Clobetasol PropionateSolution.462 mg/mLTopicalPhysicians Total Care, Inc.2005-05-12Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalIpg Pharmaceuticals, Inc.1996-07-08Not applicableUs
Clobetasol PropionateGel.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2000-02-15Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalGlenmark Pharmaceuticals., Usa2017-03-20Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalRebel Distributors1996-09-30Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalGw Pharmaceuticals Ltd.2016-01-04Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalGolden State Medical Supply1996-07-12Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalA S Medication Solutions1996-02-23Not applicableUs
Clobetasol PropionateEmulsion.5 mg/gTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalA S Medication Solutions2014-02-03Not applicableUs
Clobetasol PropionateGel.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1999-05-28Not applicableUs
Clobetasol PropionateEmulsion.5 mg/gTopicalPhysicians Total Care, Inc.2011-09-07Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalLupin Pharmaceuticals2015-11-23Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalRebel Distributors1998-11-13Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalActavis Pharma Company2014-02-03Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalPreferreed Pharmaceuticals Inc.2012-04-23Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalA S Medication Solutions1996-02-23Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1996-07-08Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalActavis Pharma Company2015-05-29Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2000-05-17Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalGolden State Medical Supply1996-07-12Not applicableUs
Clobetasol PropionateCream.5 mg/gTopicalUnit Dose Services1996-09-30Not applicableUs
Clobetasol PropionateShampoo.05 g/100mLTopicalActavis Mid Atlantic LLC,2012-01-03Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalRebel Distributors1996-02-23Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalNovel Laboratories, Inc.2015-11-23Not applicableUs
Clobetasol PropionateSolution.4625 mg/mLTopicalHi Tech Pharmacal Co., Inc.2010-06-07Not applicableUs
Clobetasol PropionateGel.05 mg/gTopicalPerrigo New York Inc.2008-07-30Not applicableUs
Clobetasol PropionateOintment.5 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.1996-07-12Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalTolmar Inc2017-02-08Not applicableUs
Clobetasol PropionateSolution.5 mg/mLTopicalMorton Grove Pharmaceuticals, Inc.1998-11-13Not applicableUs
Clobetasol Propionate (emollient)Cream.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1999-05-26Not applicableUs
Clobetasol Propionate Emollient FormulationAerosol, foam.5 mg/gTopicalPerrigo New York Inc.2013-02-01Not applicableUs
ClodanShampoo.5 mg/mLTopicalMedimetriks Pharmaceuticals2014-06-22Not applicableUs
Clodan KitKitMedimetriks Pharmaceuticals2014-06-15Not applicableUs
CormaxSolution.4625 mg/mLTopicalECR Pharmaceuticals Co., Inc.2012-07-05Not applicableUs
CormaxOintment.5 mg/gTopicalWatson Pharma, Inc.2008-09-18Not applicableUs
TemovateCream.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1985-12-27Not applicableUs
TemovateOintment.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1985-12-27Not applicableUs
Temovate ECream.5 mg/gTopicalPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1999-05-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ClobesolGlaxoSmithKline
DermovateGlaxoSmithKline
EmbelineHi-Tech
Embeline EHi-Tech
Brand mixturesNot Available
Categories
UNII779619577M
CAS number25122-46-7
WeightAverage: 466.97
Monoisotopic: 466.192230046
Chemical FormulaC25H32ClFO5
InChI KeyCBGUOGMQLZIXBE-KBUOYLHWNA-N
InChI
InChI=1/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/s2
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-14-(2-chloroacetyl)-1-fluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl propanoate
SMILES
[H][C@@]12C[[email protected]](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Structured Indications
PharmacodynamicsLike other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Mechanism of actionThe precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, however, clobetasol, like other corticosteroids, bind to the glucocorticoid receptor, which complexes, enteres the cell nucleus and modifies genetic transcription (transrepression/transactivation).
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionTopical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids, including clobetasol propionate and its metabolites, are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in rat and mouse is >3000 mg/kg. Topically applied clobetasol can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clobetasol propionate.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clobetasol propionate.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clobetasol propionate.Approved
AldesleukinClobetasol propionate may decrease the antineoplastic activities of Aldesleukin.Approved
Aluminum hydroxideThe bioavailability of Clobetasol propionate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clobetasol propionate.Approved
AmiodaroneThe serum concentration of Clobetasol propionate can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BClobetasol propionate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clobetasol propionate.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clobetasol propionate.Approved, Investigational
AprepitantThe serum concentration of Clobetasol propionate can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clobetasol propionate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clobetasol propionate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clobetasol propionate.Approved, Investigational
BazedoxifeneThe serum concentration of Clobetasol propionate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideClobetasol propionate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clobetasol propionate.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clobetasol propionate.Approved
Bismuth SubcitrateThe bioavailability of Clobetasol propionate can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Clobetasol propionate can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasol propionate.Approved
BumetanideClobetasol propionate may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clobetasol propionate.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Clobetasol propionate can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Clobetasol propionate can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clobetasol propionate.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clobetasol propionate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasol propionate.Approved, Investigational
CeritinibClobetasol propionate may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clobetasol propionate.Approved, Vet Approved
ChlorothiazideClobetasol propionate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Clobetasol propionate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneClobetasol propionate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Clobetasol propionate can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Clobetasol propionate.Approved
CobicistatThe serum concentration of Clobetasol propionate can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Clobetasol propionate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Clobetasol propionate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clobetasol propionate.Approved
DarunavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Demecarium.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clobetasol propionate.Approved, Vet Approved
DienestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol propionate.Approved
DihydrotestosteroneClobetasol propionate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clobetasol propionate.Approved
EchothiophateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Clobetasol propionate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clobetasol propionate.Approved
EstradiolThe serum concentration of Clobetasol propionate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Clobetasol propionate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clobetasol propionate can be increased when it is combined with Estrone.Approved
Etacrynic acidClobetasol propionate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Clobetasol propionate can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasol propionate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clobetasol propionate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clobetasol propionate.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clobetasol propionate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clobetasol propionate.Approved
FleroxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clobetasol propionate.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Flumequine.Withdrawn
FluoxymesteroneClobetasol propionate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clobetasol propionate.Approved, Investigational
FosaprepitantThe serum concentration of Clobetasol propionate can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Fosphenytoin.Approved
FurosemideClobetasol propionate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gallamine Triethiodide.Approved
GatifloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Clobetasol propionate can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clobetasol propionate.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Hexestrol.Withdrawn
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Clobetasol propionate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasol propionate.Approved, Investigational
HydrochlorothiazideClobetasol propionate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideClobetasol propionate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clobetasol propionate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clobetasol propionate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clobetasol propionate.Approved
IdelalisibThe serum concentration of Clobetasol propionate can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Clobetasol propionate.Approved
IndapamideClobetasol propionate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clobetasol propionate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clobetasol propionate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Clobetasol propionate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clobetasol propionate.Withdrawn
ItraconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clobetasol propionate.Experimental
KetoconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clobetasol propionate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasol propionate.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clobetasol propionate.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clobetasol propionate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clobetasol propionate.Approved
LumacaftorThe serum concentration of Clobetasol propionate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clobetasol propionate.Approved, Investigational
MagaldrateThe bioavailability of Clobetasol propionate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol propionate.Approved
Magnesium TrisilicateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clobetasol propionate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clobetasol propionate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clobetasol propionate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clobetasol propionate.Approved
MestranolThe serum concentration of Clobetasol propionate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol propionate.Withdrawn
MethallenestrilThe serum concentration of Clobetasol propionate can be increased when it is combined with Methallenestril.Experimental
MethyclothiazideClobetasol propionate may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneClobetasol propionate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneClobetasol propionate may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Clobetasol propionate can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Minaprine.Approved
MitotaneThe serum concentration of Clobetasol propionate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
MoxifloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clobetasol propionate.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol propionate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clobetasol propionate.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clobetasol propionate.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clobetasol propionate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clobetasol propionate.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Clobetasol propionate.Investigational
NefazodoneThe serum concentration of Clobetasol propionate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clobetasol propionate.Approved
NevirapineThe serum concentration of Clobetasol propionate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clobetasol propionate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasol propionate.Approved, Withdrawn
NorfloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol propionate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol propionate.Approved
OxandroloneClobetasol propionate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol propionate.Approved
OxymetholoneClobetasol propionate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clobetasol propionate.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clobetasol propionate.Approved
PefloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Clobetasol propionate can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Clobetasol propionate can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clobetasol propionate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clobetasol propionate.Approved, Vet Approved
PhenytoinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clobetasol propionate.Approved, Investigational
PiretanideClobetasol propionate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clobetasol propionate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol propionate.Approved, Investigational
PolythiazideClobetasol propionate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Clobetasol propionate can be decreased when it is combined with Primidone.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clobetasol propionate.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasol propionate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Clobetasol propionate can be increased when it is combined with Quinestrol.Approved
QuinethazoneClobetasol propionate may increase the hypokalemic activities of Quinethazone.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Clobetasol propionate.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clobetasol propionate.Experimental, Investigational
RifabutinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Clobetasol propionate can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clobetasol propionate can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with CDX-110.Investigational
RitonavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clobetasol propionate.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol propionate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clobetasol propionate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clobetasol propionate.Approved
SaquinavirThe serum concentration of Clobetasol propionate can be increased when it is combined with Saquinavir.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Clobetasol propionate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clobetasol propionate.Investigational
St. John's WortThe serum concentration of Clobetasol propionate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololClobetasol propionate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasol propionate.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clobetasol propionate.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clobetasol propionate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Clobetasol propionate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Clobetasol propionate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Clobetasol propionate.Approved
TelithromycinThe serum concentration of Clobetasol propionate can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clobetasol propionate.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clobetasol propionate.Approved
TestosteroneClobetasol propionate may increase the fluid retaining activities of Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clobetasol propionate.Approved
TiboloneThe serum concentration of Clobetasol propionate can be increased when it is combined with Tibolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clobetasol propionate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clobetasol propionate.Approved
TorasemideClobetasol propionate may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasol propionate.Approved, Investigational
TrichlormethiazideClobetasol propionate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clobetasol propionate.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clobetasol propionate.Investigational, Withdrawn
VoriconazoleThe serum concentration of Clobetasol propionate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinClobetasol propionate may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clobetasol propionate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clobetasol propionate.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clobetasol propionate.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to
Glaxo Laboratories Limited, England.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (95.3 KB)
MSDSDownload (74.6 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableModerate, refractory Atopic dermatitis1
1CompletedOtherPsoriasis1
1CompletedTreatmentPsoriasis Vulgaris2
1CompletedTreatmentModerate, refractory Atopic dermatitis1
1RecruitingOtherPsoriasis1
2CompletedTreatmentVulvar Lichen Sclerosus1
2RecruitingTreatmentColon Adenocarcinoma / Rectal Adenocarcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2RecruitingTreatmentOral Lichen Planus1
2TerminatedTreatmentVulvar Lichen Sclerosus1
3CompletedTreatmentAlopecia Areata (AA)1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentScalp Psoriasis1
4CompletedNot AvailablePsoriasis1
4CompletedTreatmentChronic Stable Plaque Psoriasis1
4CompletedTreatmentDermatitis, Chronic1
4CompletedTreatmentHand Dermatosis1
4CompletedTreatmentHypertrophic Scars1
4CompletedTreatmentPlaque Psoriasis4
4CompletedTreatmentPlaque-Type Psoriasis1
4CompletedTreatmentPsoriasis3
4CompletedTreatmentPsoriatic Nails1
4CompletedTreatmentScalp Psoriasis1
4RecruitingPreventionBullous Pemphigoid (BP)1
4Unknown StatusTreatmentAlopecia1
4Unknown StatusTreatmentDermatitis, Contact / Dermatitis, Occupational1
Not AvailableActive Not RecruitingTreatmentVulvar Lichen Sclerosus1
Not AvailableTerminatedNot AvailablePsoriasis1
Pharmacoeconomics
Manufacturers
  • Perrigo israel pharmaceuticals ltd
  • Connetics corp
  • Stiefel laboratories inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Altana inc
  • Stiefel a gsk co
  • Taro pharmaceuticals usa inc
  • Hi tech pharmacal co inc
  • Perrigo co
  • Galderma laboratories l p
  • Nycomed us inc
  • Galderma laboratories inc
  • Tolmar inc
  • Wockhardt eu operations (swiss) ag
  • Galderma laboratories lp
Packagers
Dosage forms
FormRouteStrength
LiquidTopical.05 %
CreamTopical.5 mg/g
EmulsionTopical.5 mg/g
GelTopical.05 mg/g
GelTopical.5 mg/g
LotionTopical.05 mg/100mL
LotionTopical.5 mg/mL
OintmentTopical.5 mg/g
SolutionTopical.462 mg/mL
SprayTopical.5 mg/mL
LotionTopical.05 mL/100mL
LotionTopical.05 g/100mL
ShampooTopical.05 g/100mL
SprayTopical.05 g/mL
ShampooTopical0.05 %
ShampooTopical.5 mg/mL
Kit
SolutionTopical.4625 mg/mL
SolutionTopical.05 %
CreamTopical.05 %
OintmentTopical.05 %
Aerosol, foamTopical.5 mg/g
Aerosol, foamTopical0.05 %
LiquidTopical0.05 %
CreamTopical0.05 %
LotionTopical0.05 %
OintmentTopical0.05 %
SolutionTopical0.05 %
SolutionTopical.5 mg/mL
Prices
Unit descriptionCostUnit
Clobex 0.05% Lotion 118ml Bottle513.56USD bottle
Clobex Spray 0.05% Liquid 125ml Bottle501.7USD bottle
Olux 0.05% Foam 100 gm Can443.77USD can
Olux-E 0.05% Foam 100 gm Can384.32USD can
Olux Olux-E Complete Pack 0.05 & 0.05% Miscellaneous 110 gm Can373.65USD can
Clobex 0.05% Shampoo 118ml Bottle365.67USD bottle
Clobetasol Propionate 0.05% Foam 100 gm Can326.37USD can
Clobex 0.05% Lotion 59ml Bottle280.8USD bottle
Clobex Spray 0.05% Liquid 59ml Bottle278.93USD bottle
Olux 0.05% Foam 50 gm Can239.07USD can
Temovate 0.05% Cream 60 gm Tube234.19USD tube
Temovate 0.05% Gel 60 gm Tube234.19USD tube
Temovate E 0.05% Cream 60 gm Tube234.19USD tube
Clobetasol Propionate 0.05% Foam 50 gm Can177.05USD can
Temovate 0.05% Ointment 30 gm Tube132.55USD tube
Temovate 0.05% Solution 50ml Bottle113.82USD bottle
Temovate 0.05% Cream 45 gm Tube95.43USD tube
Clobetasol Propionate 0.05% Gel 60 gm Tube93.82USD tube
Temovate 0.05% Ointment 15 gm Tube82.1USD tube
Clobetasol 17-prop powder70.74USD g
Clobetasol Propionate 0.05% Cream 60 gm Tube64.15USD tube
Clobetasol Propionate 0.05% Ointment 60 gm Tube64.15USD tube
Clobetasol Propionate 0.05% Gel 30 gm Tube51.66USD tube
Clobetasol Propionate 0.05% Ointment 45 gm Tube50.56USD tube
Clobetasol Propionate 0.05% Cream 45 gm Tube48.57USD tube
Temovate 0.05% Gel 15 gm Tube47.38USD tube
Temovate E 0.05% Cream 15 gm Tube44.9USD tube
Clobetasol Propionate 0.05% Solution 50ml Bottle41.18USD bottle
Clobetasol Propionate 0.05% Cream 30 gm Tube34.79USD tube
Clobetasol Propionate 0.05% Ointment 30 gm Tube34.79USD tube
Clobetasol Propionate 0.05% Gel 15 gm Tube28.86USD tube
Clobetasol Propionate 0.05% Solution 25ml Bottle26.99USD bottle
Clobetasol Propionate 0.05% Cream 15 gm Tube24.94USD tube
Clobetasol Propionate 0.05% Ointment 15 gm Tube24.1USD tube
Olux 0.05% foam6.77USD g
Olux-e 0.05% foam5.9USD g
Clobex 0.05% topical lotion4.58USD ml
Temovate emollient 0.05% crm3.75USD g
Olux-olux-e complete pack3.43USD g
Temovate 0.05% cream3.29USD g
Cormax 0.05% cream2.06USD g
Embeline 0.05% cream1.86USD g
Clobetasol 0.05% cream1.43USD g
Dermovate 0.05 % Cream0.72USD g
Dermovate 0.05 % Ointment0.72USD g
Dermovate 0.05 % Lotion0.63USD g
Mylan-Clobetasol 0.05 % Cream0.38USD g
Mylan-Clobetasol 0.05 % Ointment0.38USD g
Novo-Clobetasol 0.05 % Cream0.38USD g
Novo-Clobetasol 0.05 % Ointment0.38USD g
Pms-Clobetasol 0.05 % Cream0.38USD g
Pms-Clobetasol 0.05 % Ointment0.38USD g
Ratio-Clobetasol 0.05 % Cream0.38USD g
Ratio-Clobetasol 0.05 % Ointment0.38USD g
Taro-Clobetasol 0.05 % Cream0.38USD g
Taro-Clobetasol 0.05 % Ointment0.38USD g
Mylan-Clobetasol 0.05 % Lotion0.33USD g
Pms-Clobetasol 0.05 % Lotion0.33USD g
Ratio-Clobetasol 0.05 % Lotion0.33USD g
Taro-Clobetasol 0.05 % Lotion0.33USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2333427 No2007-01-092019-06-17Canada
CA2333869 No2009-01-062019-09-08Canada
US5972920 No1998-02-122018-02-12Us
US5990100 No1998-03-242018-03-24Us
US6106848 No1997-09-222017-09-22Us
US6126920 No1996-03-012016-03-01Us
US6730288 No1999-09-082019-09-08Us
US7029659 No1999-09-082019-09-08Us
US7316810 No1999-06-172019-06-17Us
US7700081 No2002-01-032022-01-03Us
US8066975 No1999-06-172019-06-17Us
US8066976 No1999-06-172019-06-17Us
US8460641 No2008-11-052028-11-05Us
US8962000 No2005-08-312025-08-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226Elks, J., Phillipps, G.H. and May, P.J.; US. Patent 3,721,687; March 20, 1973; assigned to Glaxo Laboratories Limited, England.
water solubility3.86 mg/LNot Available
logP3.50SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.49ALOGPS
logP4.18ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.63ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity119.32 m3·mol-1ChemAxon
Polarizability48.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9814
Caco-2 permeable+0.812
P-glycoprotein substrateSubstrate0.7852
P-glycoprotein inhibitor INon-inhibitor0.7375
P-glycoprotein inhibitor IINon-inhibitor0.7683
Renal organic cation transporterNon-inhibitor0.7883
CYP450 2C9 substrateNon-substrate0.8533
CYP450 2D6 substrateNon-substrate0.9077
CYP450 3A4 substrateSubstrate0.7967
CYP450 1A2 substrateNon-inhibitor0.9412
CYP450 2C9 inhibitorNon-inhibitor0.8713
CYP450 2D6 inhibitorNon-inhibitor0.8327
CYP450 2C19 inhibitorNon-inhibitor0.9126
CYP450 3A4 inhibitorNon-inhibitor0.5411
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9129
Ames testNon AMES toxic0.8848
CarcinogenicityNon-carcinogens0.935
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1435 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9314
hERG inhibition (predictor II)Non-inhibitor0.5569
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0a6r-0596000000-b19d97ac39952d18b68eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-03mj-3971000000-8f42562c23aaf5e5d240View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 9-halo-steroid
  • Halo-steroid
  • Hydroxysteroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Alpha-haloketone
  • Alpha-chloroketone
  • Cyclic alcohol
  • Carboxylic acid ester
  • Cyclic ketone
  • Fluorohydrin
  • Secondary alcohol
  • Halohydrin
  • Ketone
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organooxygen compound
  • Alcohol
  • Organic oxide
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Carbonyl group
  • Alkyl halide
  • Organofluoride
  • Alkyl chloride
  • Organochloride
  • Alkyl fluoride
  • Organohalogen compound
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG: Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med. 2006 Jan;36(1):37-43. Epub 2005 Oct 28. [PubMed:16255837 ]
  2. Hofmann TG, Hehner SP, Bacher S, Droge W, Schmitz ML: Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett. 1998 Dec 28;441(3):441-6. [PubMed:9891987 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 29, 2017 04:37